Item9B. Other Information
Not applicable.
Item10. Directors, Executive Officers and Corporate Governance
Biographies of the DirectorsWhose Terms Expire at the 2015Annual Meeting of Stockholders. These
Directors will be Nominees for Election for a Three-Year Termat the 2015Annual Meeting.
Frederick T. Muto,
age 61, has served as a Director of Isis sinceMarch 2001. Mr. Muto joined the law firm
of Cooley LLP, outside counsel to Isis, in 1980 and became a partner in 1986. He is Chair of the firm’s Business
Department and a founding partner of Cooley LLP’s San Diego office.
The Board believes Mr. Muto is uniquely suited to serve on the Board primarily because, with 35 years of
experience at one of the country’s leading law firms focused on life sciences and technology companies, he
provides us important advice regarding our strategic transactions, corporate governance and compensation
matters.
Breaux B. Castleman,
age 74, has served as a Director of Isis since June 2013. SinceAugust 2001,
Mr. Castleman has been president and chief executive officer of Syntiro Healthcare Services, Inc., a health care
investment company, which recently sold its operations as a service provider of integrated care management and
disease management. Mr. Castleman has been a director of USMDHoldings, Inc., a physician-led integrated
healthcare system, since September 2009 and was a director of MELASciences, Inc., a medical device company,
from 2003 until 2011.
The Board believes that Mr. Castleman is uniquely suited to serve on the Board and theAudit Committee
because he has significant experience in strategic planning and financial engineering for Fortune 1000 companies
and has financial advisory expertise in the life sciences industry.
Biographies of the DirectorsWhose Terms Expire at the 2016Annual Meeting of Stockholders.
Stanley T. Crooke,
M.D., Ph.D., age 69, is a founder of Isis and has been Chief Executive Officer and a
Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Isis,
from 1980 until January 1989, Dr. Crooke worked for SmithKline Beckman Corporation, a pharmaceutical
company, where his titles included President of Research and Development of SmithKline and French
Laboratories.
The Board believes Dr. Crooke is uniquely suited to serve on the Board primarily because as the Chief
Executive Officer and founder of Isis he has dedicated over 25 years to the discovery and development of
antisense, our technology platform. He is the named inventor on some of the key patents in the field of
RNA-targeted therapeutics, and has over 30 years of drug discovery and development experience.
Joseph Klein, III,
age 53, has served as a Director of Isis since December 2005. Mr. Klein is currently
Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused
on biopharmaceuticals, which he founded inMarch 1998. FromSeptember 2003 to December 2008, Mr. Klein
also served as a Venture Partner of RedAbbey Venture Partners, L.P., a life science private equity fund. From
September 2001 to September 2002, Mr. Klein was a Venture Partner of MPMCapital, a healthcare venture
capital firm. From June 1999 to September 2000 when it merged withWebMDCorporation, Mr. Klein served as
Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management
information systems. For over nine years from 1989 to 1998, Mr. Klein was a health care investment analyst at
T. Rowe PriceAssociates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health
Sciences Fund, Inc. Mr. Klein serves on the board of directors of The Prospector Funds, Inc., an SECRegistered
Investment Company that manages two no-load mutual funds. Mr. Klein also serves on the boards of private and
non-profit entities. Within the last five years, Mr. Klein formerly served on the board of directors of five publicly
held biotechnology companies: BioMarin Pharmaceutical Inc., NPS Pharmaceuticals, Inc., OSI Pharmaceuticals,
Inc., PDLBioPharma, Inc. and Savient Pharmaceuticals, Inc.
The Board believes that Mr. Klein is uniquely suited to serve on the Board and theAudit Committee
because he is a Chartered Financial Analyst, and because he has extensive public company, venture investment,
board, and financial advisory expertise in the life sciences industry.
91
